Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Data preview for Heart Rhythm Society conference in Denver this week. More research news.

You may also be interested in...

International Briefs: NICE On Sutureless Aortic Valves, Mechanical Clot Retrieval, Microsphere Cancer Therapy

In recent guidance documents, the U.K.’s National Institute for Health and Care Excellence offers tempered support for sutureless aortic valve replacement, and calls mechanical clot retrieval in stroke patients unproven and risky. Also, its support for radioactive microspheres for liver cancer depends on malignancy type.

St. Jude Medical: Cardiac Rhythm Management Business Has “Turned The Corner”

The firm reported during its second-quarter earnings call that its cardiac rhythm management business has stabilized after several quarters of market share decline.

St Jude Begins Major Lead Assessment Study

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts